Proactiveinvestors USA & Canada Q BioMed Inc. https://www.proactiveinvestors.com Proactiveinvestors USA & Canada Q BioMed Inc. RSS feed en Wed, 11 Dec 2019 10:02:10 -0500 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) Q BioMed's technology partner Mannin presents acute kidney injury treatment data https://www.proactiveinvestors.com/companies/news/907877/q-biomed-s-technology-partner-mannin-presents-acute-kidney-injury-treatment-data-907877.html Tue, 26 Nov 2019 14:55:00 -0500 https://www.proactiveinvestors.com/companies/news/907877/q-biomed-s-technology-partner-mannin-presents-acute-kidney-injury-treatment-data-907877.html Q BioMed shares soar on FDA greenlight to begin manufacturing Strontium-89 https://www.proactiveinvestors.com/companies/news/907583/q-biomed-shares-soar-on-fda-greenlight-to-begin-manufacturing-strontium-89-907583.html Thu, 21 Nov 2019 17:37:00 -0500 https://www.proactiveinvestors.com/companies/news/907583/q-biomed-shares-soar-on-fda-greenlight-to-begin-manufacturing-strontium-89-907583.html Q BioMed's manufacturer of cancer bone pain drug Strontium-89 wins FDA clearance; shares rocket https://www.proactiveinvestors.com/companies/news/907476/q-biomed-s-manufacturer-of-cancer-bone-pain-drug-strontium-89-wins-fda-clearance-shares-rocket-907476.html Thu, 21 Nov 2019 00:30:00 -0500 https://www.proactiveinvestors.com/companies/news/907476/q-biomed-s-manufacturer-of-cancer-bone-pain-drug-strontium-89-wins-fda-clearance-shares-rocket-907476.html Q BioMed CEO sees significant capital funding for next 3 years https://www.proactiveinvestors.com/companies/news/906674/q-biomed-ceo-sees-significant-capital-funding-for-next-3-years-906674.html Fri, 08 Nov 2019 17:53:00 -0500 https://www.proactiveinvestors.com/companies/news/906674/q-biomed-ceo-sees-significant-capital-funding-for-next-3-years-906674.html Q BioMed partner Mannin wins $7.5M grant from German state to develop glaucoma therapies https://www.proactiveinvestors.com/companies/news/906342/q-biomed-partner-mannin-wins-75m-grant-from-german-state-to-develop-glaucoma-therapies-906342.html Tue, 05 Nov 2019 14:58:00 -0500 https://www.proactiveinvestors.com/companies/news/906342/q-biomed-partner-mannin-wins-75m-grant-from-german-state-to-develop-glaucoma-therapies-906342.html Q BioMed gives life to undervalued biomedical assets https://www.proactiveinvestors.com/companies/news/904690/q-biomed-gives-life-to-undervalued-biomedical-assets-904690.html Tue, 15 Oct 2019 11:00:00 -0400 https://www.proactiveinvestors.com/companies/news/904690/q-biomed-gives-life-to-undervalued-biomedical-assets-904690.html Q BioMed selects 'the perfect partner' to distribute its non-opioid bone pain relief drug Strontium-89 https://www.proactiveinvestors.com/companies/news/904215/q-biomed-selects--the-perfect-partner--to-distribute-its-non-opioid-bone-pain-relief-drug-strontium-89-904215.html Fri, 04 Oct 2019 17:10:00 -0400 https://www.proactiveinvestors.com/companies/news/904215/q-biomed-selects--the-perfect-partner--to-distribute-its-non-opioid-bone-pain-relief-drug-strontium-89-904215.html Q BioMed in partnership deal to distribute non-opioid metastatic cancer drug in US https://www.proactiveinvestors.com/companies/news/904118/q-biomed-in-partnership-deal-to-distribute-non-opioid-metastatic-cancer-drug-in-us-904118.html Thu, 03 Oct 2019 14:10:00 -0400 https://www.proactiveinvestors.com/companies/news/904118/q-biomed-in-partnership-deal-to-distribute-non-opioid-metastatic-cancer-drug-in-us-904118.html Q BioMed makes headway with commercial launch of cancer bone pain drug; announces legal settlement on ownership https://www.proactiveinvestors.com/companies/news/904012/q-biomed-makes-headway-with-commercial-launch-of-cancer-bone-pain-drug-announces-legal-settlement-on-ownership-904012.html Wed, 02 Oct 2019 14:29:00 -0400 https://www.proactiveinvestors.com/companies/news/904012/q-biomed-makes-headway-with-commercial-launch-of-cancer-bone-pain-drug-announces-legal-settlement-on-ownership-904012.html Q BioMed, Chemveda to collaborate further on liver cancer treatment https://www.proactiveinvestors.com/companies/news/902514/q-biomed-chemveda-to-collaborate-further-on-liver-cancer-treatment-902514.html Wed, 11 Sep 2019 15:45:00 -0400 https://www.proactiveinvestors.com/companies/news/902514/q-biomed-chemveda-to-collaborate-further-on-liver-cancer-treatment-902514.html Q BioMed successfully synthesizes molecule to treat liver cancer in a 'tremendously exciting achievement' https://www.proactiveinvestors.com/companies/news/901174/q-biomed-successfully-synthesizes-molecule-to-treat-liver-cancer-in-a--tremendously-exciting-achievement--901174.html Tue, 20 Aug 2019 20:26:00 -0400 https://www.proactiveinvestors.com/companies/news/901174/q-biomed-successfully-synthesizes-molecule-to-treat-liver-cancer-in-a--tremendously-exciting-achievement--901174.html Q BioMed, Chemveda Life Sciences achieve potential chemotherapeutic breakthrough in liver cancer https://www.proactiveinvestors.com/companies/news/901163/q-biomed-chemveda-life-sciences-achieve-potential-chemotherapeutic-breakthrough-in-liver-cancer-901163.html Tue, 20 Aug 2019 15:23:00 -0400 https://www.proactiveinvestors.com/companies/news/901163/q-biomed-chemveda-life-sciences-achieve-potential-chemotherapeutic-breakthrough-in-liver-cancer-901163.html Q BioMed on track with commercialization of non-opioid metastatic cancer pain drug https://www.proactiveinvestors.com/companies/news/223763/q-biomed-on-track-with-commercialization-of-non-opioid-metastatic-cancer-pain-drug-223763.html Thu, 11 Jul 2019 13:45:00 -0400 https://www.proactiveinvestors.com/companies/news/223763/q-biomed-on-track-with-commercialization-of-non-opioid-metastatic-cancer-pain-drug-223763.html Q BioMed files for FDA's Orphan Drug status for its pediatric autism drug https://www.proactiveinvestors.com/companies/news/223067/q-biomed-files-for-fda-s-orphan-drug-status-for-its-pediatric-autism-drug-223067.html Fri, 28 Jun 2019 14:45:00 -0400 https://www.proactiveinvestors.com/companies/news/223067/q-biomed-files-for-fda-s-orphan-drug-status-for-its-pediatric-autism-drug-223067.html Q BioMed to apply for Orphan Drug status with FDA, European regulators for its pediatric autism drug https://www.proactiveinvestors.com/companies/news/221493/q-biomed-to-apply-for-orphan-drug-status-with-fda-european-regulators-for-its-pediatric-autism-drug-221493.html Tue, 04 Jun 2019 14:45:00 -0400 https://www.proactiveinvestors.com/companies/news/221493/q-biomed-to-apply-for-orphan-drug-status-with-fda-european-regulators-for-its-pediatric-autism-drug-221493.html Q BioMed discovers two key biomarkers in study of pediatric nonverbal autism https://www.proactiveinvestors.com/companies/news/312972/q-biomed-discovers-two-key-biomarkers-in-study-of-pediatric-nonverbal-autism-12972.html Thu, 11 Apr 2019 16:00:00 -0400 https://www.proactiveinvestors.com/companies/news/312972/q-biomed-discovers-two-key-biomarkers-in-study-of-pediatric-nonverbal-autism-12972.html Q BioMed uncovers first biomarkers for pediatric nonverbal autism https://www.proactiveinvestors.com/companies/news/218331/q-biomed-uncovers-first-biomarkers-for-pediatric-nonverbal-autism-218331.html Wed, 10 Apr 2019 13:23:00 -0400 https://www.proactiveinvestors.com/companies/news/218331/q-biomed-uncovers-first-biomarkers-for-pediatric-nonverbal-autism-218331.html Q BioMed gains on outlook for near-term development and approval of glaucoma candidates https://www.proactiveinvestors.com/companies/news/217343/q-biomed-gains-on-outlook-for-near-term-development-and-approval-of-glaucoma-candidates-217343.html Wed, 27 Mar 2019 14:24:00 -0400 https://www.proactiveinvestors.com/companies/news/217343/q-biomed-gains-on-outlook-for-near-term-development-and-approval-of-glaucoma-candidates-217343.html Q BioMed and Mannin Research to develop GDF15 biomarker glaucoma diagnostic kit with McMaster University https://www.proactiveinvestors.com/companies/news/216754/q-biomed-and-mannin-research-to-develop-gdf15-biomarker-glaucoma-diagnostic-kit-with-mcmaster-university-216754.html Tue, 19 Mar 2019 12:19:00 -0400 https://www.proactiveinvestors.com/companies/news/216754/q-biomed-and-mannin-research-to-develop-gdf15-biomarker-glaucoma-diagnostic-kit-with-mcmaster-university-216754.html Q BioMed licenses significant biomarker to diagnose glaucoma https://www.proactiveinvestors.com/companies/news/312568/q-biomed-licenses-significant-biomarker-to-diagnose-glaucoma-12568.html Tue, 12 Mar 2019 13:35:00 -0400 https://www.proactiveinvestors.com/companies/news/312568/q-biomed-licenses-significant-biomarker-to-diagnose-glaucoma-12568.html Q BioMed licenses novel biomarker for monitoring glaucoma severity from Washington University https://www.proactiveinvestors.com/companies/news/216202/q-biomed-licenses-novel-biomarker-for-monitoring-glaucoma-severity-from-washington-university-216202.html Mon, 11 Mar 2019 14:46:00 -0400 https://www.proactiveinvestors.com/companies/news/216202/q-biomed-licenses-novel-biomarker-for-monitoring-glaucoma-severity-from-washington-university-216202.html Q BioMed's Technology partner Mannin Research forges research collaboration with McMaster University for Glaucoma drug MAN-01 https://www.proactiveinvestors.com/companies/news/213357/q-biomed-s-technology-partner-mannin-research-forges-research-collaboration-with-mcmaster-university-for-glaucoma-drug-man-01-213357.html Fri, 25 Jan 2019 14:14:00 -0500 https://www.proactiveinvestors.com/companies/news/213357/q-biomed-s-technology-partner-mannin-research-forges-research-collaboration-with-mcmaster-university-for-glaucoma-drug-man-01-213357.html QBioMed appoints Yale psychologist to advisory committee https://www.proactiveinvestors.com/companies/news/212710/qbiomed-appoints-yale-psychologist-to-advisory-committee-212710.html Wed, 16 Jan 2019 14:49:00 -0500 https://www.proactiveinvestors.com/companies/news/212710/qbiomed-appoints-yale-psychologist-to-advisory-committee-212710.html QBioMed provides optimistic shareholder update https://www.proactiveinvestors.com/companies/news/212170/qbiomed-provides-optimistic-shareholder-update-212170.html Tue, 08 Jan 2019 15:08:00 -0500 https://www.proactiveinvestors.com/companies/news/212170/qbiomed-provides-optimistic-shareholder-update-212170.html Biotech CEOs see Bristol-Myers' $74B acquisition of Celgene as a win https://www.proactiveinvestors.com/companies/news/211926/biotech-ceos-see-bristol-myers--74b-acquisition-of-celgene-as-a-win-211926.html Thu, 03 Jan 2019 19:43:00 -0500 https://www.proactiveinvestors.com/companies/news/211926/biotech-ceos-see-bristol-myers--74b-acquisition-of-celgene-as-a-win-211926.html Q BioMed partners with SRI International to push potentially multi-bn product toward clinical trials https://www.proactiveinvestors.com/companies/news/311615/q-biomed-partners-with-sri-international-to-push-potentially-multi-bn-product-toward-clinical-trials-11615.html Thu, 13 Dec 2018 18:30:00 -0500 https://www.proactiveinvestors.com/companies/news/311615/q-biomed-partners-with-sri-international-to-push-potentially-multi-bn-product-toward-clinical-trials-11615.html Q BioMed partners with SRI International for autism drug QBM-001 https://www.proactiveinvestors.com/companies/news/211066/q-biomed-partners-with-sri-international-for-autism-drug-qbm-001-211066.html Wed, 12 Dec 2018 14:15:00 -0500 https://www.proactiveinvestors.com/companies/news/211066/q-biomed-partners-with-sri-international-for-autism-drug-qbm-001-211066.html Q BioMed’s Metastron acquisition ‘positive development,’ advances pipeline, says Brookline Capital Markets https://www.proactiveinvestors.com/companies/news/210227/q-biomeds-metastron-acquisition-positive-development-advances-pipeline-says-brookline-capital-markets-210227.html Thu, 29 Nov 2018 13:11:00 -0500 https://www.proactiveinvestors.com/companies/news/210227/q-biomeds-metastron-acquisition-positive-development-advances-pipeline-says-brookline-capital-markets-210227.html Q BioMed CEO 'tremendously excited' to acquire Metastron drug from GE Healthcare https://www.proactiveinvestors.com/companies/news/311353/q-biomed-ceo-tremendously-excited-to-acquire-metastron-drug-from-ge-healthcare-11353.html Wed, 28 Nov 2018 16:29:00 -0500 https://www.proactiveinvestors.com/companies/news/311353/q-biomed-ceo-tremendously-excited-to-acquire-metastron-drug-from-ge-healthcare-11353.html Q BioMed scores victory by acquiring cancer pain drug Metastron from GE Healthcare https://www.proactiveinvestors.com/companies/news/210137/q-biomed-scores-victory-by-acquiring-cancer-pain-drug-metastron-from-ge-healthcare-210137.html Wed, 28 Nov 2018 15:51:00 -0500 https://www.proactiveinvestors.com/companies/news/210137/q-biomed-scores-victory-by-acquiring-cancer-pain-drug-metastron-from-ge-healthcare-210137.html Q BioMed orphan drug exec hosts roundtable on expanded access programs https://www.proactiveinvestors.com/companies/news/207970/q-biomed-orphan-drug-exec-hosts-roundtable-on-expanded-access-programs-207970.html Fri, 26 Oct 2018 19:45:00 -0400 https://www.proactiveinvestors.com/companies/news/207970/q-biomed-orphan-drug-exec-hosts-roundtable-on-expanded-access-programs-207970.html Q BioMed plans for clinical testing with its autism drug QBM-001 https://www.proactiveinvestors.com/companies/news/310803/q-biomed-plans-for-clinical-testing-with-its-autism-drug-qbm-001-10803.html Wed, 10 Oct 2018 17:21:00 -0400 https://www.proactiveinvestors.com/companies/news/310803/q-biomed-plans-for-clinical-testing-with-its-autism-drug-qbm-001-10803.html Q BioMed offers update on its autism drug QBM-001 https://www.proactiveinvestors.com/companies/news/206691/q-biomed-offers-update-on-its-autism-drug-qbm-001-206691.html Tue, 09 Oct 2018 13:25:00 -0400 https://www.proactiveinvestors.com/companies/news/206691/q-biomed-offers-update-on-its-autism-drug-qbm-001-206691.html QBioMed reaches new $4M funding agreement with Yorkville Advisors Global https://www.proactiveinvestors.com/companies/news/205550/qbiomed-reaches-new-4m-funding-agreement-with-yorkville-advisors-global-205550.html Mon, 24 Sep 2018 13:23:00 -0400 https://www.proactiveinvestors.com/companies/news/205550/qbiomed-reaches-new-4m-funding-agreement-with-yorkville-advisors-global-205550.html Q BioMed appoints ophthalmologist Dr Rajendra Apte to its advisory board https://www.proactiveinvestors.com/companies/news/205046/q-biomed-appoints-ophthalmologist-dr-rajendra-apte-to-its-advisory-board-205046.html Mon, 17 Sep 2018 14:45:00 -0400 https://www.proactiveinvestors.com/companies/news/205046/q-biomed-appoints-ophthalmologist-dr-rajendra-apte-to-its-advisory-board-205046.html Q BioMed takes final step to gaining FDA approval to manufacture its spearhead drug https://www.proactiveinvestors.com/companies/news/310194/q-biomed-takes-final-step-to-gaining-fda-approval-to-manufacture-its-spearhead-drug-10194.html Tue, 21 Aug 2018 19:44:00 -0400 https://www.proactiveinvestors.com/companies/news/310194/q-biomed-takes-final-step-to-gaining-fda-approval-to-manufacture-its-spearhead-drug-10194.html Q BioMed takes the final step toward FDA approval of its bone pain relief injectable https://www.proactiveinvestors.com/companies/news/203238/q-biomed-takes-the-final-step-toward-fda-approval-of-its-bone-pain-relief-injectable-203238.html Mon, 20 Aug 2018 13:53:00 -0400 https://www.proactiveinvestors.com/companies/news/203238/q-biomed-takes-the-final-step-toward-fda-approval-of-its-bone-pain-relief-injectable-203238.html Q BioMed extends clinical trial agreement with Washington University to study glaucoma drugs https://www.proactiveinvestors.com/companies/news/309968/q-biomed-extends-clinical-trial-agreement-with-washington-university-to-study-glaucoma-drugs-9968.html Thu, 26 Jul 2018 16:05:00 -0400 https://www.proactiveinvestors.com/companies/news/309968/q-biomed-extends-clinical-trial-agreement-with-washington-university-to-study-glaucoma-drugs-9968.html QBioMed extends clinical trial agreement to study glaucoma drugs with Washington University https://www.proactiveinvestors.com/companies/news/201568/qbiomed-extends-clinical-trial-agreement-to-study-glaucoma-drugs-with-washington-university-201568.html Wed, 25 Jul 2018 13:54:00 -0400 https://www.proactiveinvestors.com/companies/news/201568/qbiomed-extends-clinical-trial-agreement-to-study-glaucoma-drugs-with-washington-university-201568.html Roth Capital Partners initiates coverage in Q BioMed with a Buy rating and $6.75 price target https://www.proactiveinvestors.com/companies/news/199819/roth-capital-partners-initiates-coverage-in-q-biomed-with-a-buy-rating-and-675-price-target-199819.html Thu, 28 Jun 2018 18:10:00 -0400 https://www.proactiveinvestors.com/companies/news/199819/roth-capital-partners-initiates-coverage-in-q-biomed-with-a-buy-rating-and-675-price-target-199819.html QBioMed unveils advances in its Tie2 activating molecule for use in glaucoma treatments https://www.proactiveinvestors.com/companies/news/198381/qbiomed-unveils-advances-in-its-tie2-activating-molecule-for-use-in-glaucoma-treatments-198381.html Wed, 06 Jun 2018 13:45:00 -0400 https://www.proactiveinvestors.com/companies/news/198381/qbiomed-unveils-advances-in-its-tie2-activating-molecule-for-use-in-glaucoma-treatments-198381.html Q BioMed takes a hands-on approach to autism research https://www.proactiveinvestors.com/companies/news/198117/q-biomed-takes-a-hands-on-approach-to-autism-research-198117.html Mon, 04 Jun 2018 19:37:00 -0400 https://www.proactiveinvestors.com/companies/news/198117/q-biomed-takes-a-hands-on-approach-to-autism-research-198117.html Q BioMed Inc awaits FDA approval of facility to manufacture 'revenue ready' pain drug https://www.proactiveinvestors.com/companies/news/309043/q-biomed-inc-awaits-fda-approval-of-facility-to-manufacture-revenue-ready-pain-drug-9043.html Tue, 10 Apr 2018 22:49:00 -0400 https://www.proactiveinvestors.com/companies/news/309043/q-biomed-inc-awaits-fda-approval-of-facility-to-manufacture-revenue-ready-pain-drug-9043.html Q BioMed Inc. to present at MicroCap Conference in New York City https://www.proactiveinvestors.com/companies/news/194364/q-biomed-inc-to-present-at-microcap-conference-in-new-york-city-194364.html Thu, 05 Apr 2018 15:59:00 -0400 https://www.proactiveinvestors.com/companies/news/194364/q-biomed-inc-to-present-at-microcap-conference-in-new-york-city-194364.html Q BioMed asks FDA to approve new manufacturing facility for its cancer bone pain injection https://www.proactiveinvestors.com/companies/news/193317/q-biomed-asks-fda-to-approve-new-manufacturing-facility-for-its-cancer-bone-pain-injection-193317.html Fri, 16 Mar 2018 14:06:00 -0400 https://www.proactiveinvestors.com/companies/news/193317/q-biomed-asks-fda-to-approve-new-manufacturing-facility-for-its-cancer-bone-pain-injection-193317.html Q BioMed to present at 30th annual Roth Conference https://www.proactiveinvestors.com/companies/news/192946/q-biomed-to-present-at-30th-annual-roth-conference-192946.html Fri, 09 Mar 2018 15:45:00 -0500 https://www.proactiveinvestors.com/companies/news/192946/q-biomed-to-present-at-30th-annual-roth-conference-192946.html Q BioMed beefs up its board with half an eye on listing on a national exchange https://www.proactiveinvestors.com/companies/news/191653/q-biomed-beefs-up-its-board-with-half-an-eye-on-listing-on-a-national-exchange-191653.html Tue, 13 Feb 2018 21:35:00 -0500 https://www.proactiveinvestors.com/companies/news/191653/q-biomed-beefs-up-its-board-with-half-an-eye-on-listing-on-a-national-exchange-191653.html Q Biomed gets exclusive option to license glaucoma biomarker from Washington University https://www.proactiveinvestors.com/companies/news/191410/q-biomed-gets-exclusive-option-to-license-glaucoma-biomarker-from-washington-university-191410.html Thu, 08 Feb 2018 18:36:00 -0500 https://www.proactiveinvestors.com/companies/news/191410/q-biomed-gets-exclusive-option-to-license-glaucoma-biomarker-from-washington-university-191410.html Q BioMed pulls trigger on catalyst-rich year as it brings in US$5.48mln from offering https://www.proactiveinvestors.com/companies/news/191030/q-biomed-pulls-trigger-on-catalyst-rich-year-as-it-brings-in-us548mln-from-offering-191030.html Thu, 01 Feb 2018 20:10:00 -0500 https://www.proactiveinvestors.com/companies/news/191030/q-biomed-pulls-trigger-on-catalyst-rich-year-as-it-brings-in-us548mln-from-offering-191030.html Q BioMed prices US$5.5mln offering as it's poised for catalyst-rich year https://www.proactiveinvestors.com/companies/news/190853/q-biomed-prices-us55mln-offering-as-it-s-poised-for-catalyst-rich-year-190853.html Tue, 30 Jan 2018 20:03:00 -0500 https://www.proactiveinvestors.com/companies/news/190853/q-biomed-prices-us55mln-offering-as-it-s-poised-for-catalyst-rich-year-190853.html Q BioMed shares up; Corin to present at California conference https://www.proactiveinvestors.com/companies/news/189476/q-biomed-shares-up-corin-to-present-at-california-conference-189476.html Wed, 03 Jan 2018 19:48:00 -0500 https://www.proactiveinvestors.com/companies/news/189476/q-biomed-shares-up-corin-to-present-at-california-conference-189476.html Q BioMed expects "productive and catalyst-rich" 2018 https://www.proactiveinvestors.com/companies/news/189200/q-biomed-expects-productive-and-catalyst-rich-2018-189200.html Thu, 21 Dec 2017 20:37:00 -0500 https://www.proactiveinvestors.com/companies/news/189200/q-biomed-expects-productive-and-catalyst-rich-2018-189200.html Q BioMed says all convertible notes and loans now settled https://www.proactiveinvestors.com/companies/news/188389/q-biomed-says-all-convertible-notes-and-loans-now-settled-188389.html Wed, 06 Dec 2017 16:19:00 -0500 https://www.proactiveinvestors.com/companies/news/188389/q-biomed-says-all-convertible-notes-and-loans-now-settled-188389.html Q BioMed Inc welcomes autism language expert to advisory committee https://www.proactiveinvestors.com/companies/news/187930/q-biomed-inc-welcomes-autism-language-expert-to-advisory-committee-187930.html Tue, 28 Nov 2017 19:38:00 -0500 https://www.proactiveinvestors.com/companies/news/187930/q-biomed-inc-welcomes-autism-language-expert-to-advisory-committee-187930.html Q BioMed's pipeline boosted as tech partner gets funding for glaucoma therapeutic research https://www.proactiveinvestors.com/companies/news/187236/q-biomed-s-pipeline-boosted-as-tech-partner-gets-funding-for-glaucoma-therapeutic-research-187236.html Tue, 14 Nov 2017 17:39:00 -0500 https://www.proactiveinvestors.com/companies/news/187236/q-biomed-s-pipeline-boosted-as-tech-partner-gets-funding-for-glaucoma-therapeutic-research-187236.html Biotech "accelerator" Q BioMed has several shots at goal https://www.proactiveinvestors.com/companies/news/183191/biotech-accelerator-q-biomed-has-several-shots-at-goal-183191.html Mon, 23 Oct 2017 13:13:00 -0400 https://www.proactiveinvestors.com/companies/news/183191/biotech-accelerator-q-biomed-has-several-shots-at-goal-183191.html Q BioMed keen to get into clinic after it develops new drug candidate for toddler non-verbal disorder https://www.proactiveinvestors.com/companies/news/185894/q-biomed-keen-to-get-into-clinic-after-it-develops-new-drug-candidate-for-toddler-non-verbal-disorder-185894.html Thu, 19 Oct 2017 19:16:00 -0400 https://www.proactiveinvestors.com/companies/news/185894/q-biomed-keen-to-get-into-clinic-after-it-develops-new-drug-candidate-for-toddler-non-verbal-disorder-185894.html Q BioMed announces favourable amendment to debenture financing https://www.proactiveinvestors.com/companies/news/185530/q-biomed-announces-favourable-amendment-to-debenture-financing-185530.html Thu, 12 Oct 2017 15:16:00 -0400 https://www.proactiveinvestors.com/companies/news/185530/q-biomed-announces-favourable-amendment-to-debenture-financing-185530.html Q BioMed says cancer pain drug will be available later this month https://www.proactiveinvestors.com/companies/news/185139/q-biomed-says-cancer-pain-drug-will-be-available-later-this-month-185139.html Thu, 05 Oct 2017 19:19:00 -0400 https://www.proactiveinvestors.com/companies/news/185139/q-biomed-says-cancer-pain-drug-will-be-available-later-this-month-185139.html Q BioMed strikes development deal with Sphaera Pharma to advance toddler non-verbal disorder drug https://www.proactiveinvestors.com/companies/news/184245/q-biomed-strikes-development-deal-with-sphaera-pharma-to-advance-toddler-non-verbal-disorder-drug-184245.html Tue, 19 Sep 2017 18:36:00 -0400 https://www.proactiveinvestors.com/companies/news/184245/q-biomed-strikes-development-deal-with-sphaera-pharma-to-advance-toddler-non-verbal-disorder-drug-184245.html Q BioMed's $3mln equity financing provides runway for near term goals https://www.proactiveinvestors.com/companies/news/181862/q-biomed-s-3mln-equity-financing-provides-runway-for-near-term-goals-181862.html Wed, 02 Aug 2017 13:02:00 -0400 https://www.proactiveinvestors.com/companies/news/181862/q-biomed-s-3mln-equity-financing-provides-runway-for-near-term-goals-181862.html Q BioMed eyeing two investigational new drug filings by year end https://www.proactiveinvestors.com/companies/news/180714/q-biomed-eyeing-two-investigational-new-drug-filings-by-year-end-180714.html Tue, 11 Jul 2017 16:10:00 -0400 https://www.proactiveinvestors.com/companies/news/180714/q-biomed-eyeing-two-investigational-new-drug-filings-by-year-end-180714.html Q Biomed looking at catalyst- filled year ahead, reckons SeeThruEquity https://www.proactiveinvestors.com/companies/news/180635/q-biomed-looking-at-catalyst-filled-year-ahead-reckons-seethruequity-180635.html Mon, 10 Jul 2017 20:00:00 -0400 https://www.proactiveinvestors.com/companies/news/180635/q-biomed-looking-at-catalyst-filled-year-ahead-reckons-seethruequity-180635.html Q BioMed shares nudge higher as it hires industry veteran to help commercialise bone drug https://www.proactiveinvestors.com/companies/news/179844/q-biomed-shares-nudge-higher-as-it-hires-industry-veteran-to-help-commercialise-bone-drug-179844.html Mon, 26 Jun 2017 19:33:00 -0400 https://www.proactiveinvestors.com/companies/news/179844/q-biomed-shares-nudge-higher-as-it-hires-industry-veteran-to-help-commercialise-bone-drug-179844.html Q BioMed's Denis Corin 'extremely pleased' to bring cancer pain drug to market https://www.proactiveinvestors.com/companies/news/307660/q-biomed-s-denis-corin-extremely-pleased-to-bring-cancer-pain-drug-to-market-7660.html Tue, 20 Jun 2017 09:47:00 -0400 https://www.proactiveinvestors.com/companies/news/307660/q-biomed-s-denis-corin-extremely-pleased-to-bring-cancer-pain-drug-to-market-7660.html Q BioMed strikes license deal for novel liver cancer drug https://www.proactiveinvestors.com/companies/news/179343/q-biomed-strikes-license-deal-for-novel-liver-cancer-drug-179343.html Thu, 15 Jun 2017 17:59:00 -0400 https://www.proactiveinvestors.com/companies/news/179343/q-biomed-strikes-license-deal-for-novel-liver-cancer-drug-179343.html Q Biomed to attend nuclear medicine conference https://www.proactiveinvestors.com/companies/news/179045/q-biomed-to-attend-nuclear-medicine-conference-179045.html Fri, 09 Jun 2017 17:34:00 -0400 https://www.proactiveinvestors.com/companies/news/179045/q-biomed-to-attend-nuclear-medicine-conference-179045.html Q BioMed 'looking for a significant return for shareholders' - CEO Denis Corin https://www.proactiveinvestors.com/companies/news/307610/q-biomed-looking-for-a-significant-return-for-shareholders-ceo-denis-corin-7610.html Fri, 09 Jun 2017 15:04:00 -0400 https://www.proactiveinvestors.com/companies/news/307610/q-biomed-looking-for-a-significant-return-for-shareholders-ceo-denis-corin-7610.html QBioMed commercialises cancer pain drug less than a year after licensing deal https://www.proactiveinvestors.com/companies/news/178973/qbiomed-commercialises-cancer-pain-drug-less-than-a-year-after-licensing-deal-178973.html Thu, 08 Jun 2017 18:00:00 -0400 https://www.proactiveinvestors.com/companies/news/178973/qbiomed-commercialises-cancer-pain-drug-less-than-a-year-after-licensing-deal-178973.html